Lv6
1930 积分 2024-06-14 加入
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
3个月前
已完结
Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment
3个月前
已完结
Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer
4个月前
已完结
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
4个月前
已完结
Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies
4个月前
已完结
The signaling pathways activated by ROR1 in cancer
4个月前
已完结
DDR1-targeted therapies: current limitations and future potential
4个月前
已完结
New target DDR1: A “double-edged sword” in solid tumors
4个月前
已完结
[Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)]
4个月前
已完结
Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer
5个月前
已完结
皖公网安备34019202002308
